Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.

Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Bi-and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours

Video Interview: Find out why Neo-X is so unique

Video Interview: Let's talk bispecific antibodies. 10 minutes with... Bryan Glaser, Vice President of Invenra

Workshop Speakers Include: Christian Klein, Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich | Julian Andreev, Research Fellow, Regeneron | Marlon Hinner, Principal Scientist & Group Leader, Roche Innovation Centre Munich | Danielle Mandikan, Scientist, Genentech

John Delaney, Director, Research Technologies and Collaborations, Amgen. Date of Congress: 27th - 29th April 2020

Webinar on 'Bispecific Antibodies Targeting The Innate Immune Checkpoint CD47'Hosted by Nicolas Fischer, Chief Executive Officer, Light Chain Bioscience

Antonin De Fougerolles, Chief Executive Officer, Evox Therapeutics